L'intérêt à découvert pour Biogen donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Biogen. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Biogen (NASDAQ:BIIB) Stock, Rapport sur les intérêts à découvert

Biogen

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Biogen Inc

Sage Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sage#NASDAQ">SAGE</a>) announced that partner Biogen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biib#NASDAQ">BIIB</a>) has terminated its rights related to the investigational neurology candidate, SAGE-324. A phase II study on SAGE-324 for treating essential tremor failed to meet the primary endpoint in July.
The termination will be effective from Feb. 17, 2025.
Following the termination of the deal by BIIB, Sage Therapeutics will obtain full ownership and rights of SAGE-324. The company plans to study SAGE-324 for other indications, if any.
Year to date, shares of Sage Therapeutics have plunged 66.9% compared with the industry&#39;s decrease of 1.9%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/42/79464.jpg?v=1490030544" />
Image Source: Zacks Investment Research
<h2>SAGE&#39;s Licensing Agreement With BIIB</h2>
In July, Sage Therapeutics and Biogen announced top-line data from the phase II KINETIC 2 study, which evaluated SAGE-324 as a potential treatment for ET. The study failed to demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with ET.
Based on the disappointing data, SAGE and BIIB decided to stop further clinical development of SAGE-324 in ET.
SAGE currently markets the depression drug Zurzuvae (zuranolone) in partnership with Biogen.
Zurzuvae, the first and only oral treatment indicated for adults with postpartum depression (PPD), was approved by the FDA in August 2023 and commercially launched in December.
Sage Therapeutics and Biogen, equally share profits and losses for the commercialization of Zurzuvae in the United States. In ex-U.S. markets, Biogen records product sales (excluding Japan, Taiwan and South Korea) and pays royalties to Sage Therapeutics.
Sage Therapeutics and BIIB are focused on establishing Zurzuvae as a first-line therapy and the standard of care for women with PPD.
The FDA issued a complete response letter for the new drug application (NDA) for zuranolone for treating adults with major depressive disorder in August 2023. Per the FDA, the data supporting the NDA filing did not provide substantial evidence of effectiveness to support a potential approval. It recommended conducting additional clinical studies.
The company is evaluating the necessary steps to address this CRL.
<h2>SAGE&#39;s Zacks Rank &amp; Stocks to Consider</h2>
Sage Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) and Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $2.09 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 43.8%.
KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, with the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.33 to 28 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.14. Year to date, shares of FULC have plunged 40.8%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2342709/sage-biib-end-collaboration-for-neurology-candidate-sage-324?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2342709">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Earnings Beats

Large Cap

Mid Cap

News

Penny Stocks

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

BIIB

FULC

KRYS

SAGE

SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324

On Thursday, Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) announced that Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) had terminated its rights under the collaboration and license agreement with Sage, which was specific to the <a href="https://www.benzinga.com/pressreleases/24/09/b41042766/sage-therapeutics-announces-discontinuation-of-the-collaboration-with-biogen-on-the-sage-324-progr" target="_blank" rel="noreferrer noopener">SAGE-324 program</a>.
The companies recently announced negative results from the Phase 2 KINETIC 2 Study of investigational SAGE-324 for the chronic treatment of essential tremor (ET) and discontinued further clinical development of SAGE-324 in ET.
Essential tremor is&nbsp;a neurological disorder that causes involuntary shaking or trembling in certain body parts.
In July, the companies announced results from the Phase 2 KINETIC 2 dose-range study of SAGE-324 (BIIB124) as a potential treatment for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39935226/sage-biogen-shelve-development-of-nervous-system-disorder-drug-after-data-disappoints" rel="noreferrer noopener">essential tremor (ET)</a>.
The KINETIC 2 Study did not demonstrate a statistically significant dose-response relationship in change from baseline to Day 91 based on the primary endpoint, The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale (PS) Item 4 (upper limb) total score.
TETRAS is used to quantify the severity of tremors and their impact on daily living activities.
Given these results, Sage and Biogen will close the ongoing open-label safety study of SAGE-324 in ET and do not plan to conduct further clinical development of SAGE-324 in ET.
Under the terms of the collaboration and license agreement, the termination will be effective on February 17, 2025, and Sage will resume full ownership of the SAGE-324 asset.
Sage plans to continue to evaluate other potential indications, if any, for SAGE-324.
Sage and Biogen will continue to partner on Zurzuvae (zuranolone), the first and only FDA-approved oral treatment for women with postpartum depression.
Price Action: At the last check on Thursday, SAGE stock was up 1.42% at $7.12, and BIIB stock was up 1.77% at $192.42.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41046115/why-is-pasithea-therapeutics-stock-surging-on-thursday" target="_blank" rel="noreferrer noopener">Why Is Pasithea Therapeutics Stock Surging On Thursday?</a></li>
</ul>

Health Care

Contracts

Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate

The companies recently announced negative results from the Phase 2 KINETIC 2 Study of investigational SAGE-324 for the chronic treatment of essential tremor (ET) and discontinued further clinical development of SAGE-324 in ET.&nbsp;

Sage Therapeutics Announced That Biogen Has Terminated Its Rights Under The Collaboration And License Agreement With Sage Specific To The SAGE-324 Program

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and maintains $285 price target.

Price Target

Reiteration

Needham Reiterates Buy on Biogen, Maintains $285 Price Target

Tuesday, UCB SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJY#OTC">UCBJY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJF#OTC">UCBJF</a>)&nbsp;and&nbsp;Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)&nbsp;released topline results from the Phase 3 PHOENYCS GO study of dapirolizumab pegol for moderate-to-severe systemic <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40994898/ucb-and-biogen-announce-positive-topline-results-from-phase-3-study-of-dapirolizumab-pegol-in-syst" rel="noreferrer noopener">lupus erythematosus (SLE)</a>.
SLE is&nbsp;a chronic autoimmune disease that can affect many organs in the body.&nbsp;It occurs when the body&#8217;s immune system attacks healthy tissue, causing inflammation and sometimes permanent tissue damage.
SLE can present itself in several ways, including rash, arthritis, anemia, thrombocytopenia, serositis, nephritis, seizures or psychosis.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40514109/biogens-alzheimers-drug-secures-uk-approval-but-an-independent-agency-does-not-recommend-reimburs" rel="noreferrer noopener">Biogen&#8217;s Alzheimer&#8217;s Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement</a>.
Dapirolizumab pegol, in addition to standard-of-care (SOC) treatment, met the primary endpoint to demonstrate greater improvement of moderate-to-severe disease activity after 48 weeks versus placebo in addition to SOC. The study enrolled 321 patients.
Clinical improvements were observed among key secondary endpoints measuring disease activity and flares.
The safety profile of dapirolizumab pegol was generally consistent with previous studies and with that expected in study participants with systemic lupus erythematosus receiving an immunomodulator.
UCB and Biogen are initiating a second Phase 3 trial of dapirolizumab pegol in 2024, PHOENYCS FLY.
Participants from the PHOENYCS GO study will continue to be followed in a long-term open-label study.
Detailed results from the PHOENYCS GO study will be presented at an upcoming medical congress.
Price Action: At last check Tuesday, BIIB stock was up 1.66% at $199.06 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40997350/totalenergies-secures-7-year-lng-deal-with-hd-hyundai-chemical-expanding-reach-in-asias-energy-m" target="_blank" rel="noreferrer noopener">TotalEnergies Secures 7-Year LNG Deal With HD Hyundai Chemical: Expanding Reach In Asia&#8217;s Energy Market</a>.</li>
</ul>

UCBJF

UCBJY

Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial

<a href="https://www.globenewswire.com/Tracker?data=QOxRsnrI4lIcPvAJOHMkqpD2ZCcXLqncOnt8jZtYl5Orntqk98Ug6cXUt26iWYSQ">UCB</a> (Euronext Brussels: UCB) and <a href="https://www.globenewswire.com/Tracker?data=dQmAuZ_6afdr57GCMIz_bBuykaXWwgeC4T9F0-q_hAYdmPT_oUGMDy50CId7wM1j4bYykSMNSRmZ3zuqKQjiUA==">Biogen Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) today announced positive topline results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, in people living with moderate-to-severe systemic lupus erythematosus (SLE). Dapirolizumab pegol, in addition to standard-of-care (SOC) treatment, met the primary endpoint to demonstrate greater improvement of moderate-to-severe disease activity as assessed by achievement of British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) after 48 weeks versus placebo in addition to SOC. Clinical improvements were observed among key secondary endpoints measuring disease activity and flares.
The safety profile of dapirolizumab pegol was generally consistent with previous studies and with that expected in study participants with systemic lupus erythematosus receiving an immunomodulator.
"These positive results with dapirolizumab pegol represent encouraging progress in the development of medicines that can improve the lives of those living with lupus, an area that remains one of high unmet medical need and where women are disproportionately affected," said Fiona du Monceau, Head of Patient Evidence at UCB. "We have confidence in the unique mode of action of dapirolizumab pegol which targets multiple inflammatory pathways involved in the pathogenesis of SLE. As we pursue the next steps in the clinical development of this potentially differentiated treatment, we extend our appreciation to the patients, study investigators and the clinical community for their ongoing support and participation in this important research."
Based on the successful outcome of the PHOENYCS GO study, UCB and Biogen are initiating a second Phase 3 trial of dapirolizumab pegol in 2024, PHOENYCS FLY. Participants from the PHOENYCS GO study will continue to be followed in a long-term open-label study.
"Our hypothesis is that impacting the CD40L pathway, a central mechanism in immune response, would translate to significant impact on SLE disease burden. These results demonstrate that dapirolizumab pegol has the promise to provide meaningful benefit in this serious, chronic, and often devastating disease," said Diana Gallagher, MD, Head of AD, MS and Immunology Development Units at Biogen. "We are committed to delivering new treatment options for this autoimmune disease and believe the overall efficacy and safety seen in PHOENYCS GO support further development of dapirolizumab pegol in SLE."
PHOENYCS GO (n= 321) is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study of dapirolizumab pegol as an add on therapy to standard of care compared to placebo with standard of care. The primary outcome measure was improvement of moderate-to-severe disease activity at Week 48 using BICLA, an established, composite primary efficacy endpoint for measurement of clinical disease activity based on patient medical history, clinical examination and laboratory tests.
Detailed results from the PHOENYCS GO study will be presented at an upcoming medical congress.

UCB And Biogen Report Results In Phase 3 Lupus Drug Trial

20 analysts have expressed a variety of opinions on Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Biogen, presenting an average target of $273.75, a high estimate of $317.00, and a low estimate of $190.00. This current average represents a 2.96% decrease from the previous average price target of $282.10. 
<img src="https://www.benzinga.com/files/images/story/2024/1727100049_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Biogen among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$292.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Eric Schmidt</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$292.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$251.00</td>
<td>$277.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$302.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$285.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$292.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$225.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$244.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$190.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$288.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$294.00</td>
<td>$316.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$294.00</td>
<td>$294.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$313.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$294.00</td>
<td>$294.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$317.00</td>
<td>$317.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$317.00</td>
<td>$317.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Biogen. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Biogen compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Biogen's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Biogen's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biogen analyst ratings.</a>
<h2>All You Need to Know About Biogen</h2>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
<h3>Breaking Down Biogen's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Biogen's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 0.36%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Biogen's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 23.68%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Biogen's ROE excels beyond industry benchmarks, reaching 3.75%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Biogen's ROA excels beyond industry benchmarks, reaching 2.19%. This signifies efficient management of assets and strong financial health.
Debt Management: Biogen's debt-to-equity ratio is below the industry average at 0.42, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 20 Analyst Projections For Biogen

Wedbush analyst Laura Chico maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Neutral and lowers the price target from $210 to $205.

Wedbush Maintains Neutral on Biogen, Lowers Price Target to $205

RBC Capital analyst Brian Abrahams reiterates Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Outperform and maintains $292 price target.

RBC Capital Reiterates Outperform on Biogen, Maintains $292 Price Target

Biogen Executive Says Company Expects Immunogenicity Data To Be Ready By October To Submit To FDA for Subcutaneous Leqembi Filing

Eli Lilly and Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for treating moderate-to-severe atopic dermatitis, also called eczema. Ebglyss is approved for use in adults and children aged 12 and above who weigh at least 40 kgs and whose moderate-to-severe atopic dermatitis is not well controlled with topical prescription medicines.
Ebglyss was approved in the European Union in 2023 and in Japan in January this year. The drug generated sales of $7.5 million in the first half of 2024.
Year to date, Lilly&#39;s stock has risen 58.5% compared with the industry&#39;s 25.2% growth. The stock has also outperformed the sector as well as the S&amp;P 500.
<h2>LLY Stock Outperforms Industry, Sector &amp; S&amp;P 500</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/93/77794.jpg?v=624696101" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>More on LLY&#39;s Ebglyss</h2>
Ebglyss&#39; approval in the United States was based on data from&nbsp;ADvocate 1, ADvocate 2 and ADhere studies. Data from these studies showed that patients treated with Ebglyss experienced significant skin clearance as early as four weeks and meaningful itch relief as early as two weeks. Many people living with eczema experience poor long-term disease control and severe itch despite treatment with topicals. Ebglyss offers such patients a new first-line biologic treatment option for treating their moderate-to-severe eczema. The injection will be launched in the United States in the coming weeks.
In the United States and some countries other than Europe, Lilly owns exclusive development and commercialization rights to Ebglyss. However, in Europe, it has out-licensed rights to develop and commercialize Ebglyss for the treatment of dermatology indications to its partner Almirall.
<h2>Lilly&#39;s Several New Drug Approvals in Past Year</h2>
Lilly gained approvals for some other new drugs in the past year, with the most important being Mounjaro and Zepbound. &nbsp;Mounjaro and Zepbound include the same compound, tirzepatide, a dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA). Mounjaro was approved in May 2022 for type II diabetes. Zepbound was launched in November 2023 to treat obesity.
Despite a short time on the market, Mounjaro and Zepbound have become key top-line drivers for Lilly in 2024, with demand rising rapidly. Mounjaro and Zepbound generated sales of almost $6.7 billion in the first half of 2024, accounting for around 44% of the company&#39;s total revenues.
Other than Mounjaro and Zepbound, other new drug approvals include Omvoh for ulcerative colitis and BTK inhibitor Jaypirca for mantle cell lymphoma and chronic lymphocytic leukemia. Lilly expects its new drugs &mdash; Mounjaro, Omvoh, Zepbound, Ebglyss and Jaypirca &mdash; to drive its top line in the second half of 2024.
In July, Lilly won a long-awaited FDA approval for Kisunla (donanemab) for treating early symptomatic Alzheimer&#39;s disease. Lilly believes Kisunla can generate blockbuster sales. Kisunla is only the second drug on the market to treat Alzheimer&#39;s disease after Biogen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biib#NASDAQ">BIIB</a>) and its Japan-based partner Eisai&#39;s Leqembi.
<h2>Lilly&#39;s Zacks Rank and Other Stocks to Consider</h2>
Lilly sports a Zacks Rank #1 (Strong Buy).
<div class="chart_embed">
<h3>Eli Lilly and Company Stock Price and Consensus</h3>
<img alt="Eli Lilly and Company Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/84/1726472114.png" style="height:265px; width:591px" title="" />
Eli Lilly and Company price-consensus-chart | Eli Lilly and Company Quote
Some other top-ranked large drugmakers are Novartis (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvs#NYSE">NVS</a>) and Pfizer (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>), each carrying a Zacks Rank #2 (Buy).
</div>
In the past 60 days, 2024 earnings estimates for Pfizer have improved from $2.38 per share to $2.62 per share. For 2025, earnings estimates have improved from $2.75 per share to $2.85 per share over the same timeframe. Pfizer shares have risen 1.6% year to date.
Pfizer&#39;s earnings beat estimates in each of the last four quarters. PFE delivered a four-quarter average earnings surprise of 69.82%
Estimates for Novartis&#39; 2024 earnings have risen from $7.31 to $7.50 per share over the past 60 days. For 2025, earnings estimates have increased from $8.21 to $8.29 per share over the same timeframe. Year to date, Novartis stock has risen 14.5 %.
Novartis beat estimates in three of the last four quarters while missing in one, delivering a four-quarter average earnings surprise of 1.26%.
<a href="https://www.zacks.com/stock/news/2336877/lilly-gets-fda-approval-for-eczema-drug-ebglyss?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2336877">To read this article on Zacks.com click here.</a>

Lilly Gets FDA Approval for Eczema Drug Ebglyss

Global

Biogen's New Drug Submission For Omaveloxolone Accepted For Priority Review By Health Canada For The Treatment Of Friedreich's Ataxia; Regulatory Decision On New Drug Submission For Omaveloxolone Is Anticipated In Early 2025

Bio-Thera Solutions, Ltd. today announced, in collaboration with Biogen, the publication in the journal Arthritis Research &amp; Therapy of results from Treatment Period 2 (TP2; study weeks 24-48) of a Phase 3 clinical study evaluating BAT1806/BIIB800, an approved biosimilar to Actemra&#xAE;/RoActemra&#xAE;3 (tocilizumab). BAT1806/BIIB800 is currently commercialized under the brand name TOFIDENCE&#x2122;4.
&nbsp;
<ul>
<li>Comparable clinical efficacy and safety&nbsp;in Treatment Period 2 (TP2, Week 24-48) is maintained after switch from reference tocilizumab to TOFIDENCE (BAT1806/BIIB800)</li>
<li>Phase 3 clinical data in totality demonstrates biosimilarity between TOFIDENCE (BAT1806/BIIB800) and reference tocilizumab before and after switching.1,2</li>
</ul>

Bio-Thera Solutions, Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE, An Approved Biosimilar Referencing Tocilizumab In Arthritis Research & Therapy

CCCC

C4 Therapeutics Has Delivered A Second Development Candidate To Biogen And Earned An $8M Milestone Payment. This Marks The Final Development Candidate Under This Strategic Collaboration

Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediately.
What Happened: Montarce, who joined Lilly in 2001, has held numerous finance leadership positions. His roles included group vice president, corporate controller, and CFO of Lilly Research Laboratories; vice president, finance and CFO of Lilly International; and vice president, finance, and global CFO of Elanco Health.
Most recently, Montarce served as Lilly&#8217;s president and general manager for the Spain, Portugal, and Greece hub. He holds a bachelor&#8217;s degree in business accounting from Catholic University (Argentina) and a master&#8217;s degree in business administration from the Center for Macroeconomic Studies of Argentina.
David Ricks, chair and CEO stated, &#8220;We are excited to announce Lucas as Lilly&#8217;s next CFO, following a competitive search across health care, tech, and general industries.&#8221;
Montarce expressed his commitment to building on Lilly&#8217;s strong financial foundation and driving continued success. &#8220;I am honored to step into this role during such a significant time in our company&#8217;s history,&#8221; he said.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40758803/did-a-potential-stock-sale-by-elon-musk-lead-to-fall-in-tesla-shares-top-analyst-sa?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Did A Potential Stock Sale By Elon Musk Lead To Fall In Tesla Shares? Top Analyst Says It Could Instead Be Because Of Broader Selloff In AI Stocks</a>
Why It Matters: The appointment of Montarce as CFO comes at a pivotal time for Eli Lilly. The company has been in the spotlight for its <a href="https://www.benzinga.com/markets/equities/24/08/40594187/eli-lilly-is-the-nvidia-of-weight-loss-and-glp-1-space-says-roundhill-investments-ceo-emphasizes">advancements in the weight loss and GLP-1 space</a>. Roundhill Investments CEO Dave Mazza recently likened Eli Lilly to NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) in terms of market leadership and growth potential.
Additionally, Eli Lilly&#8217;s Alzheimer&#8217;s drug, donanemab, is facing potential rejection by the U.K.&#8217;s National Health Service (NHS) due to <a href="https://www.benzinga.com/general/biotech/24/08/40551066/eli-lillys-alzheimers-drug-faces-uk-agency-block-after-biogens-medicine-rejection-over-cost-safet">cost and safety concerns</a>, following a similar decision on Biogen Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) Leqembi. This has added pressure on the company to navigate regulatory challenges effectively. 
Montarce&#8217;s appointment also <a href="https://www.benzinga.com/news/24/07/39717304/eli-lilly-announces-cfo-change">follows the resignation</a> of former CFO Anat Ashkenazi, who left to pursue a new career. Gordon Brooks has been serving as interim CFO since Jul. 15. 
Moreover, Eli Lilly is intensifying its efforts to combat imitation <a href="https://www.benzinga.com/markets/equities/24/09/40672154/eli-lilly-launches-discounted-mounjaro-and-zepbound-as-fight-against-compounded-imitations-escal">versions of its popular appetite-suppressing drugs</a>, Mounjaro and Zepbound. This move is part of a broader strategy to maintain its market position amid ongoing FDA debates about drug shortages.
Price Action: Eli Lilly and Co closed at $908.27 on Monday, gaining 0.62% for the day. In after-hours trading, the stock dipped 0.027%. Year to date, Eli Lilly&#8217;s stock has surged 53.37%, according to <a href="https://pro.benzinga.com/dashboard">data from Benzing Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40782192/job-slowdown-headhunters-are-on-a-roll-revenue-for-executive-searches-is-up">Job Slowdown? Headhunters Are On A Roll, Revenue For Executive Searches Is Up</a></li>
</ul>
Image Via Shutterstock 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Equities

NVDA

Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know

Sen. Bernie Sanders (I-Vt.) recently shared his thoughts on the state of healthcare in the United States, highlighting the disparity in outcomes between those with means and those without.
What Happened: On Tuesday, Senator Sanders took to X to voice his concerns about the high cost of medical care in the U.S. and the financial burden it places on patients.
He said, &#8220;If you&#8217;re rich in America, the odds are you&#8217;ll live as long as people in other developed countries.&#8221; However, conversely, if you&#8217;re poor &#8220;you&#8217;ll live 10 or 15 years less.&#8221; 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If you&#39;re rich in America, the odds are you&#39;ll live as long as people in other developed countries. If you&#39;re poor, you&#39;ll live 10 or 15 years less. Anybody else see a problem with that? <a href="https://t.co/KGodx0ZNFg">pic.twitter.com/KGodx0ZNFg</a>
&mdash; Bernie Sanders (@SenSanders) <a href="https://twitter.com/SenSanders/status/1833265671108759908?ref_src=twsrc%5Etfw">September 9, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/24/09/40767879/veteran-pollster-weighs-in-on-new-trump-vs-harris-poll-that-shows-ex-president-closing-in-if-you-sup?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Veteran Pollster Weighs In On New Trump Vs. Harris Poll That Shows Ex-President Closing In: &#8216;If You Support Policies That 60% Of The Country Opposes…You&#8217;re Asking For Trouble&#8217;</a>
The Vermont senator shared a video in which he addressed the issue. He said when asked about the status of the current healthcare system most people without exception say that &#8220;our healthcare system today is broken.&#8221;
He said, &#8220;When people say that they are right.&#8221; Sanders added, &#8220;In America today we spend twice as much per person on healthcare as do the people of any other country.&#8221; However, he noted that the U.S. outcomes were worse in comparison.
&#8220;Our life expectancy is way down behind many other countries and really obscenely the life expectancy in the United States between the people on top and working-class people is 10-12 years.&#8221;
Why It Matters: Sanders&#8217; views come in the wake of ongoing discussions about healthcare reform in the U.S. His comments on drug pricing are particularly relevant given his previous criticisms of companies like Biogen and Bristol-Myers Squibb for their high drug prices. <a href="https://www.benzinga.com/news/24/07/39784920/bernie-sanders-getting-sick-in-america-should-not-mean-going-bankrupt-losing-your-home-car-or-life-s">Sanders has previously stated</a> that &#8220;getting sick in America should not mean going bankrupt, losing your home, car, or life savings.&#8221;
Furthermore, Sanders&#8217; comments on the upcoming elections highlight his belief that the choice is clear for voters who want to see a change in the current healthcare system. <a href="https://www.benzinga.com/general/politics/24/08/40448543/bernie-sanders-trump-just-wants-to-give-billionaires-another-tax-break-this-november-the-choice-">He has previously criticized</a> policies that favor billionaires over the average citizen.
Image via Shutterstock
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?'

Cantor Fitzgerald analyst Eric Schmidt reiterates Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Overweight and maintains $292 price target.

Cantor Fitzgerald Reiterates Overweight on Biogen, Maintains $292 Price Target

Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) and Eisai Ltd&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ESALY#OTC">ESALY</a>) Alzheimer&#8217;s drug Leqembi (lecanemab) is reportedly offering hope for patients in the early stages of the disease despite it not being a cure.
For many, like Mississippi English professor Missie Meeks, the treatment is helping to slow the progression of Alzheimer&#8217;s, allowing her to maintain independence in daily life.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40711363/biogens-higher-dose-spinraza-shows-to-slow-neurodegeneration-faster-in-infants-with-rare-neuromus" rel="noreferrer noopener">Biogen&#8217;s Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder</a>.
Meeks, who was diagnosed with Alzheimer&#8217;s ahead of her 50th birthday, has been receiving biweekly infusions of Leqembi since September 2023, giving her more time to function independently, even if the treatment hasn&#8217;t eliminated her cognitive struggles.
Leqembi, a monoclonal antibody, moderately slows memory and cognitive decline in patients with mild cognitive impairment.
While the drug represents a significant advancement, its rollout has faced several logistical challenges, including diagnostic bottlenecks, insurance issues, and a limited number of neurologists qualified to prescribe it.
Patients need to undergo extensive testing, including PET and MRI scans, to confirm their eligibility, with some clinics even requiring genetic testing due to the drug&#8217;s potential side effects, like brain swelling and bleeding.
Concerns remain over the drug&#8217;s side effects and long-term benefits.
Some neurologists are cautious about prescribing it, while others acknowledge the difficulties in managing its rollout, citing the steep learning curve.
Despite these concerns, CNBC <a target="_blank" href="https://www.cnbc.com/2024/09/08/leqembi-alzheimers-patients-biogen-eisai.html" rel="noreferrer noopener">writes</a> that the patients believe the treatment&#8217;s benefits outweigh the risks.
Sales of Leqembi have grown since its approval in July 2023, with Biogen reporting nearly $60 million in revenue from the drug in the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40105919/biogen-q2-earnings-beats-consensus-lifts-2024-profit-forecast-as-new-drug-launches-expected-to-of" rel="noreferrer noopener">first half of 2024</a>.
The company is working on simplifying treatment administration, including potential subcutaneous injections and extended infusion intervals, to make the drug more accessible for patients.
In August, Biogen&#8217;s lecanemab became the first treatment for early AD (MCI and mild dementia due to AD) that targets an underlying cause of the disease to be authorized&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40551066/eli-lillys-alzheimers-drug-faces-uk-agency-block-after-biogens-medicine-rejection-over-cost-safet" rel="noreferrer noopener">in a European country</a>.
Despite the approval, the National Institute for Health and Care Excellence (NICE), in its guidance draft,&nbsp;<a target="_blank" href="https://www.nice.org.uk/news/articles/benefits-of-new-alzheimer-s-treatment-lecanemab-are-too-small-to-justify-the-cost-to-the-nhs" rel="noreferrer noopener">said</a>, &#8220;benefits of the new Alzheimer&#8217;s drug lecanemab are too small to justify the costs.&#8221;
Price Action: At last check on Monday, BIIB stock was down 0.43% to $199.71.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40754632/doubleverifys-politics-focused-inflammatory-news-category-rolls-out-on-meta-details" target="_blank" rel="noreferrer noopener">DoubleVerify&#8217;s Politics-Focused Inflammatory News Category Rolls Out On Meta: Details</a>.</li>
</ul>

ESALY

Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges

Wednesday, Biogen&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) revealed topline data from the pivotal cohort (Part B) of the Phase 2/3 DEVOTE study evaluating the safety and efficacy of a higher dose regimen of nusinersen in treatment-naïve, symptomatic infants with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40704317/biogen-announces-positive-topline-results-from-study-of-higher-dose-regimen-of-nusinersen-showing-" rel="noreferrer noopener">spinal muscular atrophy (SMA)</a>.
The investigational higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and a higher maintenance regimen, 28 mg, every four months, compared to the approved nusinersen 12 mg regimen (Spinraza).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40551066/eli-lillys-alzheimers-drug-faces-uk-agency-block-after-biogens-medicine-rejection-over-cost-safet" rel="noreferrer noopener">Eli Lilly&#8217;s Alzheimer&#8217;s Drug Faces UK Agency Block After Biogen&#8217;s Medicine Rejection Over Cost, Safety</a>.
The study met its primary endpoint at six months, achieving a statistically significant improvement in motor function in infants who received the higher dose regimen compared to a prespecified matched sham (untreated) control group from the ENDEAR study.
&#8220;The encouraging topline results from DEVOTE show that the higher dose regimen can slow neurodegeneration faster, as shown by greater reductions in neurofilament at day 64 relative to the approved dose. Over time, the higher dose regimen led to meaningful clinical benefit in infants with symptomatic SMA,&#8221; said Stephanie Fradette, Head of the Neuromuscular Development Unit at Biogen.
Results favored the higher dose regimen relative to sham across secondary endpoints and trended in favor of the higher dose regimen over the currently approved 12mg regimen on key biomarker and efficacy measures.
The higher dose regimen was generally well tolerated, with reported adverse events generally consistent with SMA and the known safety profile of nusinersen.
Spinraza is approved in more than 71 countries to treat infants, children, and adults with spinal muscular atrophy (SMA).
As a foundation of care in SMA, more than 14,000 individuals have been treated with Spinraza worldwide.
Price Action: At last check on Wednesday, BIIB stock was up 0.76% to $206.40.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40707614/rare-disease-focused-ascendis-pharma-stock-falls-on-underwhelming-q2-earnings-guidance-cut" target="_blank" rel="noreferrer noopener">Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut</a>.</li>
</ul>

Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder

In the latest quarter, 17 analysts provided ratings for Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $275.65, along with a high estimate of $317.00 and a low estimate of $190.00. Experiencing a 3.34% decline, the current average is now lower than the previous average price target of $285.18. 
<img src="https://www.benzinga.com/files/images/story/2024/1725454852_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Biogen. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$285.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$251.00</td>
<td>$277.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$302.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$285.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$292.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$225.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$244.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$190.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$288.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$294.00</td>
<td>$316.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$294.00</td>
<td>$294.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$313.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$294.00</td>
<td>$294.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$317.00</td>
<td>$317.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$317.00</td>
<td>$317.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biogen. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Biogen compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Biogen's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Biogen's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biogen analyst ratings.</a>
<h2>Unveiling the Story Behind Biogen</h2>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
<h3>Financial Milestones: Biogen's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Biogen displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 0.36%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Biogen's net margin is impressive, surpassing industry averages. With a net margin of 23.68%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.75%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Biogen's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.19% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Biogen's debt-to-equity ratio is below the industry average. With a ratio of 0.42, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From Biogen Analyst Ratings

Needham analyst Ami Fadia has maintained their bullish stance on BIIB stock, giving a Buy rating on September 19. Ami Fadia has given his Buy ratin...

Buy Rating Affirmed for Biogen on Promising Phase 3 Results and Strategic Development Plans for Lupus Drug Dapi

TD Cowen analyst Phil Nadeau has maintained their bullish stance on BIIB stock, giving a Buy rating today. Phil Nadeau has given his Buy rating due...

Buy Rating Affirmed for Biogen Amid Surprising Success of Lupus Drug Dapirolizumab Pegol

The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of new therapeutics, and increased R&D spending on treatments for new and rare diseases. Hence, investors should consider strong biotech stocks such as Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which could deliver big gains. Keep reading… The biotech sector is rapidly expanding due to the rising global demand for therapeutics, and the development, manufacturing, and commercialization of medicines for various diseases, such as cancer and neurodegenerative disorders. This dynamic landscape presents savvy investors with opportunities to capitalize on significant profit potential.
In this favorable environment, investors might consider investing in fundamentally strong biotech stocks like Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>), Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>), and Biogen Inc. (<a href="https://stocknews.com/stock/BIIB/">BIIB</a>) for potential substantial gains.
The biotech sector targets new and rare diseases, emphasizing innovative vaccines and therapies. The increasing incidence of various illnesses demands greater R&amp;D investments and advancements in biotechnology to enhance prevention and treatment across all age groups. This growing demand for personalized medicine, coupled with supportive government initiatives, significantly boosts sales in the biotech industry.
Consequently, the global biotechnology market is projected to reach $3.88 trillion by 2030, growing at a <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">CAGR of 14%</a>. Notably, the future of biotech appears promising, driven by sophisticated innovations such as gene editing, CRISPR diagnostics, bioprinting, and tissue engineering. Moreover, the integration of AI enhances accessibility and affordability, instilling optimism in the biotech sector's potential.
Furthermore, investors' interest in biotech stocks is evident from the SPDR S&amp;P Biotech ETF's (<a href="https://stocknews.com/stock/XBI/">XBI</a>) 36% returns over the past year. Considering these conducive trends, let's analyze the fundamental aspects of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> picks, beginning with the third choice.
Stock #3: Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>)
AMGN discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/haematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Its product portfolio includes Enbrel, Neulasta, Prolia, and Xgeva.
On June 6, 2024, AMGN announced FDA approval of BLINCYTO for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase. This marks the third indication for BLINCYTO and demonstrated superior overall survival versus chemotherapy alone.
On August 20, 2024, AMGN announced that Otezla (apremilast) is now available in the U.S. for treating moderate to severe plaque psoriasis in children and adolescents aged 6-17. It is the first FDA-approved oral treatment for this condition in this age group.
AMGN's trailing-12-month <a href="https://www.investopedia.com/terms/g/gross_profit_margin.asp">gross profit margin</a> of 63.41% is 10.6% higher than the industry average of 57.35%. Likewise, its trailing-12-month EBIT margin and levered FCF margin of 20.99% and 9.74% are 628% and 492.5% higher than the industry averages of 2.88% and 1.64%, respectively.
During the fiscal second quarter, which ended on June 30, 2024, AMGN's total revenues and non-GAAP operating income increased by 20.1% and 10.2% year-over-year, reaching $8.39 billion and $3.87 billion, respectively. Moreover, its non-GAAP net income grew marginally compared to the previous year, reaching $2.69 billion. Also, its non-GAAP earnings per share was $4.97.
Analysts expect AMGN's revenue for the quarter ending September 30, 2024, to increase 23.3% year-over-year to $8.51 billion. Its EPS for the same quarter is expected to grow 3.7% year-over-year to $5.14. The company surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, the stock has gained 25.4%, closing the last trading session at $335.61.
AMGN's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its positive prospects. It has an overall B rating, equating to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
AMGN has a B grade for Quality. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #17 out of 335 stocks. <a href="https://stocknews.com/stock/AMGN/">Click here</a> for the additional POWR Ratings of AMGN (Growth, Value, Momentum, Stability, and Sentiment).
Stock #2: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>)
REGN discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection, Dupixent injection, Libtayo injection, Praluent injection, REGEN-COV for COVID-19, and Kevzara solution.
On September 13, 2024, REGN and Sanofi announced that the FDA approved Dupixent for adolescents aged 12-17 with chronic rhinosinusitis with nasal polyps (CRSwNP). Dupixent is now the first and only treatment available for this age group with inadequately controlled CRSwNP.
On August 26, 2024, REGN announced that the European Commission approved Ordspono (odronextamab) for treating relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. This is REGN's first bispecific antibody approval, offering an off-the-shelf treatment option with the potential for complete remission.
In terms of the trailing-12-month levered FCF margin, REGN's 15.50% is significantly higher than the 1.64% industry average. Similarly, its 30.14% trailing-12-month EBIT margin is 945.6% higher than the 2.88% industry average. Moreover, its 5.50% trailing-12-month Capex / Sales is 65.5% higher than the industry average of 3.32%.
In the fiscal second quarter, which ended on June 30, 2024, REGN's revenues amounted to $3.55 billion indicating a 12.3% increase year-over-year. Likewise, the company's non-GAAP net income rose 14.3% from the year-ago value to $1.35 billion, while its non-GAAP net income per share grew 12.9% year-over-year to $11.56.
Street expects REGN's EPS and revenue for the quarter ending September 30, 2024, to increase 1.5% and 8.7% year-over-year to $11.76 and $3.66 billion, respectively. It surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past year, the stock has gained 32.4%, closing the last trading session at $1,091.98.
REGN's positive outlook is reflected in its POWR Ratings. It has an overall rating of B, equating to a Buy in our proprietary rating system.
It has a B grade for Value and Quality. Within the same industry, it is ranked #9. Beyond what we stated above, we also have given REGN grades for Growth, Momentum, Stability, and Sentiment. Get all the REGN ratings <a href="https://stocknews.com/stock/REGN/">here</a>.
Stock #1: Biogen Inc. (<a href="https://stocknews.com/stock/BIIB/">BIIB</a>)
BIIB discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Asia, and internationally.
On August 22, 2024, BIIB and Eisai announced that their Alzheimer's drug Leqembi (lecanemab) was authorized for early Alzheimer's treatment in Great Britain. It is the first medicine in Europe targeting the underlying cause of Alzheimer's disease to be approved.
In terms of the trailing-12-month EBITDA margin, BIIB's 28.22% is 331.2% higher than the 6.54% industry average. Likewise, its 76.45% trailing-12-month gross profit margin is 33.3% higher than the 57.35% industry average. In addition, its 13.09% trailing-12-month levered FCF margin is 696.4% higher than the 1.64% industry average.
For the fiscal second quarter (ended June 30, 2024), BIIB's total revenue increased marginally year-over-year to $2.46 billion. Its non-GAAP net income attributable for the quarter amounted to $770.90 million, or $5.28 per share, up 31.9% and 31.3%, respectively, from the same period last year. Additionally, its free cash flow rose 42.4% year-over-year to $592.30 million.
For the quarter ending December 31, 2024, BIIB's EPS and revenue are expected to increase 14.7% and 2.4% year-over-year to $3.38 and $2.44 billion, respectively. BIIB surpassed the EPS estimates in three of the trailing four quarters. Over the past month, the stock has declined 4.5% to close the last trading session at $195.81.
It's no surprise that BIIB has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It is ranked #7 in the Biotech industry. It has an A grade for Value and a B for Growth. <a href="https://stocknews.com/stock/BIIB/">Click here</a> to see BIIB's Momentum, Stability, Sentiment, and Quality ratings.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
AMGN shares were trading at $332.28 per share on Tuesday afternoon, down $3.33 (-0.99%). Year-to-date, AMGN has gained 17.91%, versus a 20.81% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/amgn-regn-biib-3-biotech-stocks-that-could-deliver-big-gains/>3 Biotech Stocks That Could Deliver Big Gains</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks That Could Deliver Big Gains

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Biogen (BIIB – Research Report) and keeping the price target at $291.00. Teren...

Biogen's Promising Lupus Drug Garners Buy Rating: A Financial Analysis of Dapirolizumab Pegol's Market Potential

Barclays analyst Charles Pitman CFA maintained a Hold rating on Biogen (BIIB – Research Report) yesterday and set a price target of $190.00. Charle...

Hold Rating on Biogen Amidst Positive Lupus Trial Data and Pending Developments

Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), retaining the price target of $225.00. Mohit Bansa...

Maintaining Hold on Biogen Amid Uncertain Efficacy and Competitive SLE Market

Evan Seigerman, an analyst from BMO Capital, has initiated a new Buy rating on Biogen (BIIB). Evan Seigerman has given his Buy rating due to a comb...

Biogen's Clinical Triumph Spurs Buy Rating Amidst Market Opportunity

Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed's recent rate cut. To capitalize on this opportunity, consider investing in fundamentally sound biotech stocks Biogen (BIIB), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN), that are poised to skyrocket. Learn more... The biotech industry is experiencing significant growth as it continues to innovate in medicine and life sciences. With rising demand for therapeutics and new treatments targeting several complex diseases such as cancer, Alzheimer's, and rare genetic disorders, the sector is buzzing with potential.
Amid this backdrop, investors looking to gain from this momentum could scoop up the shares of fundamentally sound biotech companies like Biogen Inc. (<a href="https://stocknews.com/stock/BIIB/">BIIB</a>), BioMarin Pharmaceutical Inc. (<a href="https://stocknews.com/stock/BMRN/">BMRN</a>), and Royalty Pharma plc (<a href="https://stocknews.com/stock/RPRX/">RPRX</a>) with promising upside potential.
Analysts believe the Federal Reserve's recent rate cuts could further boost the biotech sector. John Maraganore, former CEO of Alnylam Pharmaceuticals, emphasized that the cut "will be very positive for the biotech capital markets," predicting a meaningful uptick in the sector as rates decline. Lower rates mean reduced borrowing costs, allowing biotech firms to raise more capital for their research and development (R&amp;D) projects, potentially accelerating their breakthroughs.
Moreover, the global biotechnology market is anticipated to reach <a href="https://www.precedenceresearch.com/biotechnology-market#:~:text=The%20global%20biotechnology%20market%20size%20accounted%20for%20USD%201.55%20trillion%20in%202024%20and%20is%20expected%20to%20reach%20around%20USD%204.61%20trillion%20by%202034%2C%20expanding%20at%20a%20CAGR%20of%2011.5%25%20from%202024%20to%202034.">$4.61 trillion by 2034</a>, growing at a CAGR of 11.5%. With a focus on next-generation therapies such as gene editing, immunotherapy, and biologics, biotech companies are at the forefront of medical innovation, creating a favorable environment for breakthroughs in life-saving treatments.
With that in mind, let's evaluate the fundamentals of the featured <a href="https://stocknews.com/category/biotech/">Biotech</a> industry stocks, starting with number three:
Stock #3: Royalty Pharma plc (<a href="https://stocknews.com/stock/RPRX/">RPRX</a>)
RPRX operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry. The company's portfolio consists of royalties on nearly 35 commercial products and 14 development-stage product candidates that address therapeutic areas like diabetes, cancer, neuroscience, immunology, respiratory, and hematology.
On September 3, RPRX and Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S (<a href="https://stocknews.com/stock/ASND/">ASND</a>), entered into a royalty funding agreement of $150 million based on U.S. net sales of Yorvipath. This transaction supports the continued development and commercialization of Endocrine Rare Disease products.
On May 28, RPRX announced its acquisition of Agios Pharmaceuticals' royalty on Servier's vorasidenib for $905 million cash. The vorasidenib would be the first targeted therapy for patients with IDH-mutant glioma if approved by the U.S. Food and Drug Administration (FDA).
RPRX for the second quarter (ended June 30, 2024) reported portfolio receipts of $608 million, indicating an 11.6% growth from the prior year quarter. Its operating income increased 8.4% year-over-year to $270 million. In addition, its adjusted EBITDA grew 12.4% from the prior year's quarter to $560 million.
The company's net income and <a href="https://www.investopedia.com/terms/e/eps.asp">EPS</a> attributable stood at $102 million and $0.23, respectively. Also, the non-GAAP portfolio cash flow came in at $574 million, up 11.2% year-over-year.
The company has updated its fiscal year 2024 financial outlook, increasing its revenue projection to a range of $2.70 billion to $2.78 billion, up from the previous estimate of $2.60 billion to $2.70 billion.
Analysts expect RPRX's revenue for the third quarter (ending September 2024) to grow 39.6% year-over-year to $748.66 million, while its EPS for the same period is expected to increase 16.7% from the prior year to $0.92.
Shares of RPRX have surged 5.2% over the past year to close the last trading session at $27.71. The 12-month median price target of $46.33 indicates <a href="https://www.tipranks.com/stocks/rprx/forecast">a 67.3% upside potential</a> from the last closing price. The price targets range from a low of $38 to a high of $51.
RPRX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
RPRX has a B grade for Growth and Sentiment. It is ranked #33 out of 335 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. <a href="https://stocknews.com/stock/RPRX/">Click here</a> to see the additional ratings for RPRX (Value, Momentum, Stability, and Quality).
Stock #2: BioMarin Pharmaceutical Inc. (<a href="https://stocknews.com/stock/BMRN/">BMRN</a>)
BMRN develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company is a biotechnology company addressing the root cause of genetic conditions.
On July 24, BMRN announced that the U.S. FDA approved BRINEURA (cerliponase alfa) for children under three years with neuronal ceroid lipofuscinosis type 2 (CLN2 disease). The approval expands the treatment to all ages, including presymptomatic children, to slow the loss of ambulation.
In the fiscal second quarter that ended on June 30, 2024, BMRN's total revenue increased 19.6% year-over-year to $712.03 million. The company reported non-GAAP income from operations of $221.80 million, indicating 71.7% growth from the prior-year quarter. BMRN's non-GAAP net income came in at $188.90 million, up 79.6% year-over-year, while its non-GAAP EPS grew 77.8% from the year-ago value to $0.96.
According to the updated financial guidance for fiscal year 2024, the company's revenue is now projected to be between $2.75 billion and $2.83 billion, with non-GAAP operating margin anticipated to fall between 26% and 27%. Its non-GAAP EPS is expected to range from $3.10 to $3.25.
The consensus revenue estimate of $703.13 million for the fiscal third quarter (ending September 2024) represents a 20.9% increase year-over-year. The consensus EPS estimate of $0.80 for the same quarter indicates a 73.3% improvement year-over-year. The company has an impressive earnings surprise history; it surpassed the consensus EPS estimates in three of the trailing four quarters.
The stock has surged marginally intraday to close the last trading session at $69.48. Its 12-month <a href="https://www.tipranks.com/stocks/bmrn/forecast">price target of $105.52</a> reflects a 51.9% potential upside. The price targets range from a low of $72 to a high of $132.
It's no surprise that BMRN has an overall rating of B, equating to a Buy in our POWR Ratings system. It has an A grade for Growth and a B for Value and Sentiment. Out of 335 stocks in the same industry, BMRN is ranked #14.
Beyond what is stated above, we've also rated BMRN for Momentum, Stability, and Quality. Get all BMRN ratings <a href="https://stocknews.com/stock/BMRN/">here</a>.
Stock #1: Biogen Inc. (<a href="https://stocknews.com/stock/BIIB/">BIIB</a>)
BIIB is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies worldwide for people with serious and complex diseases. The company has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). 
On August 22, BIIB and Eisai Co., Ltd. announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain granted marketing authorization to its Leqembi&#xAE;, the humanized amyloid-beta (Aβ) monoclonal antibody.
On July 30, BIIB, Beckman Coulter, Inc., and Fujirebio announced a collaboration to potentially identify and develop accessible, minimally invasive blood-based biomarkers specific for tau-pathology in the brain. These tools have the potential to be used to stratify patients or monitor treatment response for a new generation of future therapies impacting tau pathology in Alzheimer's disease.
For the second quarter of 2024, which ended on June 30, BIIB's total revenues increased marginally year-over-year to $2.46 billion. Its non-GAAP total net income attributable for the quarter amounted to $770.90 million or $5.28 per share, representing increases of 31.9% and 31.3%, respectively, from the same period last year.
Per the updated financial guidance for the fiscal year 2024, BIIB now forecasts non-GAAP EPS between $15.75 and $16.25, up from the previous estimate of $15 and $16.
Street expects BIIB's revenue for the fiscal fourth quarter (ending December 2024) to increase 2.4% year-over-year to $2.44 billion. Its EPS for the same period is expected to register a 14.7% growth from the prior year, settling at $3.38. In addition, it surpassed the EPS estimates in three of the trailing four quarters, which is promising.
BIIB's stock has declined 0.9% intraday to close the last trading session at $194.12. Its 12-month price target of $274.84 indicates <a href="https://www.tipranks.com/stocks/biib/forecast">a 41.6% potential upside</a>. The price targets range from a low of $190 to a high of $342.
BIIB's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It also has an A grade for Value and a B for Growth. Within the Biotech industry, it is ranked #8. <a href="https://stocknews.com/stock/BIIB/">Click here</a> to see BIIB's ratings for Momentum, Stability, Sentiment, and Quality.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
BIIB shares were trading at $190.22 per share on Wednesday afternoon, down $3.90 (-2.01%). Year-to-date, BIIB has declined -26.49%, versus a 21.09% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/biib-rprx-bmrn-asnd-3-biotech-stocks-wall-street-predicts-will-skyrocket/>3 Biotech Stocks Wall Street Predicts Will Skyrocket</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks Wall Street Predicts Will Skyrocket

Roche, Biogen kidney disease drug hits main goal in late-stage study

Biogen to end Sage deal for neuro candidate

AMGN

ASND

BMRN

REGN

RHHBF

RHHBY

RPRX

Press Releases

New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alzheimer's Association International Conference (AAIC) 2024

Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen

Opinion

As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032

Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth

Legal

Long Term Investor News: Biogen, Seritage Growth, Arbor Realty, and Five Below Investors are Encouraged to Contact Johnson Fistel, LLP for Their Options

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

Long-Term Investor News: Biogen, Seritage Growth, Arbor Realty, and Five Below Investors are Encouraged to Contact Johnson Fistel, LLP for Their Options

Management

Biogen Board Appoints Two New Independent Directors

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

Comments

Biogen

Intérêt court

Biogen (NASDAQ:BIIB) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL